Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Axonyx Inc (AXYX) -- Ignore unavailable to you. Want to Upgrade?

To: fmikehugo who wrote (16)	1/26/2005 9:27:49 AM
From: Jagfan	Read Replies (1) \| Respond to of 22

Thanks. After doing a little digging I came up with two possible reasons for the decline, CEO Marvin Hausman filed with the SEC to sell 60,000 shares in the next 90 days. Hausman is the third-largest holder of Axonyx stock with 2.4 million shares. If Hausman is privy to any results phase III trial data for Phenserine I think he would be selling a lot more. This being only 2.5% of his holding I'm inclined to think this is just his prearranged selling to diversify. The other reason is last week's report that Johnson & Johnson's Alzheimer's treatment, Reminyl, had a higher death rate than placebo in clinical trials.